title: Intravenous immunoglobulin use for neurologic diseases.
abstract: Intravenous immunoglobulin (IVIG) has been used primarily for immune deficiency patients, and its greatest expansion is seen more and more in the treatment of autoimmune disorders, especially in neurology. The benefits of IVIG treatment include its availability in all treatment centers and its ease of administration in an outpatient setting. This article gives an overview of some autoimmune neurologic diseases and explores the clinical evidence supporting the use of IVIG.
authors.affiliation: University of Maryland School of Medicine, Baltimore, USA.
authors.forename: Carol Lee
authors.initials: CL
authors.lastname: Koski
authors.forename: Jardiolyn Valino
authors.initials: JV
authors.lastname: Patterson
mesh_terms: D000208:Acute Disease; D000553:Ambulatory Care; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D003882:Dermatomyositis / Q000188:drug therapy; D019317:Evidence-Based Medicine; D020275:Guillain-Barre Syndrome / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D018579:Patient Selection; D010951:Plasma Exchange; D017285:Polymyositis / Q000188:drug therapy; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors